The purpose of this study was to evaluate the outcome of children with acute lymphoid leukemia (ALL) in second remission who have undergone high-dose chemotherapy and radiotherapy and autologous bone marrow transplantation (ABMT) with monoclonal antibody purged marrow, and to determine the main prognostic factors. From 1987 to 1992, 55 children with ALL in second remission underwent ABMT. The conditioning regimen consisted of total body irradiation (TBI) plus cyclophosphamide in 21 patients and TBI plus cyclophosphamide plus cytarabine or VP-16 in 28 patients; the remaining six patients were treated with chemotherapy alone (cyclophosphamide and busulfan, and/or VP-16). The marrow was purged using monoclonal antibodies and complement or magnetic microspheres in all cases. All patients engrafted. Three patients (5%) died early post transplant from infections. Twenty-six patients (47%) relapsed (median 150 days); 26 patients (47%) are alive and in complete remission (CR) at a median of 36 months. The Kaplan-Meier estimation showed a probability of event-free survival (EFS) of 46 ؎ 0.007%. In the univariate analysis, first CR length and conditioning with TBI plus two or more cytotoxic drugs were found to be the most significant predictors of EFS. ABMT with purged marrow is a treatment modality which offers a chance of cure in children with ALL after relapse, including children who relapse early.
Although the long-term survival for children with acute lymphoblastic leukemia (ALL) has improved in the last decades and has achieved an EFS of approximately 70%, [1] [2] [3] the optimal treatment after relapse remains controversial. [4] [5] [6] Allogeneic bone marrow transplantation (allo-BMT) from an HLA-identical donor is generally considered to be the treatment of choice for these patients. 7, 8 Autologous BMT (ABMT) is an alternative approach for children without an Correspondence: MS Maldonado, Servicio de Pediatría, Ramón y Cajal Hospital, 28034 Madrid, Spain Received 16 June 1998; accepted 23 July 1998 appropriate donor, but does not have the graft-versus-leukemia effect of allo-BMT. Moreover, harvested marrow may contain residual tumor cells. An attempt to reduce this risk has been made by using pharmacological or immunological techniques to purge leukemia cells from bone marrow in vitro. 9 We report the results of a retrospective study of 55 children with ALL in second complete remission (2CR) who received high doses of radiotherapy and/or chemotherapy followed by reinfusion of autologous bone marrow purged in vitro with monoclonal antibodies.
Patients and methods

Patient characteristics
From July 1987 to July 1994, 55 children (38 boys and 17 girls) with ALL in 2CR underwent ABMT with immunological purging in three Spanish pediatric BMT units (Ramón y Cajal Hospital, Madrid; Valle de Hebrón and San Pablo Hospital, Barcelona). The median age at the time of ABMT was 8 years (range 3-17 years). Informed consent was given by the parents in all cases.
The patients were diagnosed between 1982 and 1994 and treated with multi-agent chemotherapy according to protocols in use during this period at these three centers and other referring institutions. 2, 10, 11 Reinduction therapy after relapse included vincristine, prednisone, asparaginase and an anthracycline. Remission was defined as the absence of extramedullary leukemia and a percentage of blasts in bone marrow (BM) of less than 5%. 12 The first CR had a median duration of 27 months (range 3-109 months). We defined early relapse (ER) as occurring within 30 months of diagnosis and late relapse (LR) as occurring after 30 months from diagnosis (ie more than 6 months after discontinuing therapy). Thirty-two children had an ER; this group included all the 14 patients with isolated extramedullary relapse (CNS = 7, testicular = 6, eye = 1). LR was observed in 23 patients (BM = 18 and combined = 5). The median interval from second CR to ABMT was 4 months (range 2-13 months). Patient characteristics are given in Table 1 . 
Transplant methodology
Bone marrow was harvested in two patients in first CR, and in second CR in the remaining patients. A purging procedure with monoclonal antibodies (moAb) coupled to complement (n = 48) or immunomagnetic microspheres (n = 7) was subsequently performed. 13, 14 Depending on the patient's ALL immunophenotype, the following moAb cocktails were used: c-ALL and B-ALL (anti-CD9, anti-CD10, anti-CD19 and anti-CD20); T-ALL (anti-CD2, antiCD3, anti-CD4, anti-CD6 and anti-CD8).
Conditioning consisted of fractionated total body irradiation (TBI) (200 cGy twice daily for 3 days), cyclophosphamide (120 mg/kg for 2 days) and Ara-C (18 g/m 2 for 3 days) in 23 patients. Twenty-one children received TBI and cyclophosphamide at the same dose as above. TBI, cyclophosphamide and VP-16 (45-60 mg/kg for 1 day) were used in five patients. The remaining six patients were conditioned with chemotherapy alone: busulfan (16 mg/kg for 4 days) and cyclophosphamide and/or VP-16 at the same dose as above.
Statistical analysis
The Kaplan-Meier estimation 15 was used for evaluation of EFS, and the log-rank test to compare the Kaplan-Meier curves. 16 Multivariate analysis was performed using the Cox proportional hazards regression model. 17 EFS included either relapses or deaths in second remission as failures. Follow-up time or the time to the terminal event were calculated from the day of transplantation. The data were analyzed in March 1998.
Results
Purging
The percentage of mononuclear cells lost during the purging process was 43.5% (range 0-84%). The median number of mononuclear cells infused was 3.3 ϫ 10 7 /kg (range 0.5-8 ϫ 10 7 /kg). The percentage of CD34 ϩ cells before purging ranged from 0.5 to 8% of low density bone marrow cells. The median percentage of CD34 ϩ cells recovered after purging was 58.4% (range 34-96%).
Hematopoietic reconstitution
All the patients engrafted; a neutrophil count above 0.5 ϫ 10 9 /1 was reached at a median time of 33 days (range 12-52 days) and a platelet count above 50 ϫ 19 9 /1 at a median of 33 days (range 12-74 days).
Transplant-related mortality
Three patients (5%) died from infectious complications (two from cytomegalovirus pneumonia at days ϩ60 and ϩ90, and one from Streptococcus viridans sepsis at day ϩ30).
Relapses
Twenty-seven of 55 children relapsed (18 from the ER group and nine from the LR group) at a median of 5 months (2-36 months). Twenty-five patients died and the remaining two are alive after reaching a third CR with conventional chemotherapy.
Event-free survival
Twenty-five patients (45%) are currently alive and remain disease-free after ABMT at a median follow-up of 76 months (range 41-113 months). Thirteen were transplanted after LR and 12 after ER. Of the 12 surviving patients in the ER group, six had presented with an extramedullary relapse. The probability of EFS at 6 years after ABMT is 45 Ϯ 6% (Figure 1) .
In the univariate analysis of factors influencing EFS, the following parameters were studied: site of relapse, duration of first CR, type of conditioning and interval between relapse and ABMT. First CR duration (LR vs ER) significantly influenced EFS (56 vs 37%; P = 0.036). If patients with extramedullary relapse are excluded, the EFS was 33%. The conditioning regimens with TBI ϩ two chemotherapeutic agents (cyclophosphamide ϩ VP-16 or Ara-C) improved EFS as compared with TBI ϩ cyclophosphamide alone (60 vs 28%, respectively; P = 0.04). Site of relapse and interval between relapse and ABMT did not make a significant impact on EFS.
The duration of first CR and conditioning regimen were not significant in the multivariate analysis. Table 2 ure 1 show the results of the univariate and multivariate analyses.
Discussion
After allogeneic BMT, a long-term survival rate of 40-70% has been reported for children with ALL transplanted in second CR from HLA-matched sibling donors. 7, 8 BMT is therefore considered to offer a better chance of cure than conventional chemotherapy, particularly in patients with ER. 18 This treatment is only available for 15-20% of children. Experience in ALL with allogeneic BMT using a matched unrelated or mismatched related donor is still limited, and carries a high risk of transplant-related morbidity and mortality, basically due to severe GVHD. [19] [20] [21] ABMT is a therapeutic modality that can be used in most children with ALL after relapse. EFS rates in children who have undergone ABMT with purged marrow cluster between 25 and 35%, with variable follow-up times. 6, 12, 22, 23 Our results, with an estimated EFS of 45% at 6 years, compare favorably with previous studies of patients in second CR treated with ABMT and purged marrow. Billet et al 22 reported an EFS of 32% in a group of 66 children. A comparative study from the EBMT showed an EFS at 6 years of 33%. 24 The duration of first CR before ABMT was significantly related to EFS in our patients (P = 0.036), as previously reported by Sallan et al. 25 Schmid et al 12 reported an EFS of 0% in their patients with a first remission of Ͻ24 months. The overall estimated EFS in our children with ER was 37%, and 33% if patients with extramedullary relapse are excluded. In children with late relapse, a survival rate of 40-60% has been recently reported with conventional chemotherapy alone. 18, 26 This treatment generally has a duration of at least 2 years. Our findings show that we have achieved similar results with ABMT and purged marrow. This procedure has a low toxicity-related morbidity and mortality, has a shorter duration than conventional chemotherapy and offers children a better quality of life.
Although site of relapse was not a statistically significant factor in our experience, it was the only independent variable that influenced survival in an Italian Study of ABMT in children with ALL in second CR. 23 In this study, the estimated EFS at 5 years was 70% for extramedullary relapses vs 13% for patients with BM relapse. For patients with isolated extramedullary relapses, a good outcome has been reported in recent studies with the use of intensive salvage therapy. 27, 28 In our study, six of 14 children (41%) remain in continuous CR, and to date no neurological sequelae have been observed. Similar results with ABMT have been reported in another recent Italian Study which compared ABMT and chemotherapy in CNS relapses. 29 Although no definitive conclusions can be established from these experiences, extramedullary relapses appear to be treatable with ABMT.
Relapse of leukemia is the most important cause of failure in patients undergoing ABMT. Potential residual disease might be reduced by increasing efficacy of conditioning regimens. Most centers have used a combination of TBI and cyclophosphamide. The Dana Farber Cancer Institute investigators, adding etoposide to this combination, reported an estimated EFS of 64% in a group of patients with ER. 22 In our study, the use of a second chemotherapeutic agent (cytosine arabinoside or etoposide) with TBI and cyclophosphamide significantly increased survival rate (60 vs 28%, P = 0.04).
Another potential problem associated with ABMT is the risk of reinfusion of residual leukemic cells in the harvested marrow, which has also been described in PBPC (peripheral blood progenitor cell) grafts collected from ALL patients in a recent study. Several techniques for purging such cells have been attempted by physical procedures, in vitro drug treatment and monoclonal antibody-based approaches. 22, 23, 30 Our results, using monoclonal antibodies, are superior to those achieved with in vitro chemotherapy. 13 Although no controlled study of purging has yet been undertaken, 9 it has been demonstrated to be a safe procedure and engraftment is not delayed. 31 In our series, early sustained engraftment was achieved in all patients, and our transplant-related mortality rate was 5%.
Our results, and those reported elsewhere, indicate that ABMT with purged marrow is a treatment modality which offers a chance of cure in children with ALL after relapse including patients with ER.
